• Consensus Rating: Buy
  • Consensus Price Target: 5.50
  • Forecasted Upside: 71.34 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
3.21
▼ -0.03 (-0.93%)

This chart shows the closing price for ME by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 23andMe Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ME

Analyst Price Target is 5.50
▲ +71.34% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for 23andMe in the last 3 months. The average price target is 5.50, with a high forecast of 7.00 and a low forecast of 3.00. The average price target represents a 71.34% upside from the last price of 3.21.

This chart shows the closing price for ME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in 23andMe. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2022CowenInitiated CoverageOutperform$6.00Low
9/22/2022CowenInitiated CoverageOutperform$6.00Low
5/27/2022Credit Suisse GroupLower TargetOutperform$11.00 ➝ $7.00High
5/27/2022CitigroupLower TargetNeutral$6.00 ➝ $3.00High
2/11/2022Credit Suisse GroupLower TargetOutperform$14.00 ➝ $11.00High
2/11/2022CitigroupLower Target$9.00 ➝ $6.00High
12/20/2021CitigroupLower TargetNeutral$13.00 ➝ $9.00Low
11/14/2021CitigroupDowngradeBuy ➝ Neutral$12.00 ➝ $13.00High
11/11/2021Credit Suisse GroupBoost TargetOutperform$13.00 ➝ $14.00High
8/16/2021Credit Suisse GroupInitiated CoverageOutperform$13.00High
8/16/2021CitigroupLower TargetBuy$14.00 ➝ $12.00High
7/12/2021CitigroupInitiated CoverageBuy$14.00Low
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/10/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/9/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
5/9/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
6/8/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/7/2022
  • 4 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
9/6/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/6/2022

Current Sentiment

  • 4 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

23andMe logo
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: 3.21
Low: 3.14
High: 3.30

50 Day Range

MA: 3.41
Low: 2.77
High: 5.12

52 Week Range

Now: 3.21
Low: 2.12
High: 13.68

Volume

61,609 shs

Average Volume

3,727,041 shs

Market Capitalization

$1.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of 23andMe?

The following Wall Street analysts have issued stock ratings on 23andMe in the last year: Citigroup Inc., Cowen Inc, Cowen Inc., and Credit Suisse Group AG.
View the latest analyst ratings for ME.

What is the current price target for 23andMe?

4 Wall Street analysts have set twelve-month price targets for 23andMe in the last year. Their average twelve-month price target is 5.50, suggesting a possible upside of 71.3%. Credit Suisse Group AG has the highest price target set, predicting ME will reach 7.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of 3.00 for 23andMe in the next year.
View the latest price targets for ME.

What is the current consensus analyst rating for 23andMe?

23andMe currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ME will outperform the market and that investors should add to their positions of 23andMe.
View the latest ratings for ME.

What other companies compete with 23andMe?

How do I contact 23andMe's investor relations team?

23andMe's physical mailing address is 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012. The company's listed phone number is 650-938-6300 and its investor relations email address is [email protected] The official website for 23andMe is vgacquisition.com. Learn More about contacing 23andMe investor relations.